JG
IOVA icon

Joel Greenblatt’s Iovance Biotherapeutics IOVA Stock Holding History

Joel Greenblatt’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-61,009
Closed -$573K – 1469
2024
Q3 		$573K Buy
+61,009
New +$578K 0.01% 1069
2022
Q2 		– Sell
-10,381
Closed -$173K – 1185
2022
Q1 		$173K Buy
+10,381
New +$161K 0.01% 1091

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Joel Greenblatt's IOVA Position: Q4 2024 in Review

Joel Greenblatt sold out of Iovance Biotherapeutics (IOVA) in Q4 2024, closing a stake of 61,009 shares — an estimated $573K sold.

Joel Greenblatt first reported a position in IOVA in Q1 2022 and held it in 2 quarters. The position peaked at $573K in Q3 2024. 301 funds tracked by Wall St. Rank hold IOVA as of Q4 2024.

  • Joel Greenblatt reported no remaining Iovance Biotherapeutics position as of Q4 2024 after selling out during the quarter.
  • Joel Greenblatt sold 61,009 Iovance Biotherapeutics shares in Q4 2024, an estimated $573K.
  • Joel Greenblatt first reported a position in Iovance Biotherapeutics in Q1 2022 and held it in 2 quarters.
  • Joel Greenblatt's Iovance Biotherapeutics position peaked at $573K in Q3 2024.
  • 301 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2024.

Based on Gotham Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.